Eversept Partners LP Reduces Stock Holdings in Puma Biotechnology, Inc. (NASDAQ:PBYI)

Eversept Partners LP trimmed its holdings in shares of Puma Biotechnology, Inc. (NASDAQ:PBYI - Free Report) by 23.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 996,102 shares of the biopharmaceutical company's stock after selling 297,155 shares during the quarter. Eversept Partners LP owned 2.03% of Puma Biotechnology worth $3,038,000 at the end of the most recent reporting period.

Other institutional investors also recently added to or reduced their stakes in the company. LPL Financial LLC increased its position in shares of Puma Biotechnology by 23.6% during the fourth quarter. LPL Financial LLC now owns 26,567 shares of the biopharmaceutical company's stock worth $81,000 after acquiring an additional 5,080 shares during the period. Prudential Financial Inc. grew its stake in Puma Biotechnology by 5.8% in the fourth quarter. Prudential Financial Inc. now owns 106,285 shares of the biopharmaceutical company's stock worth $324,000 after purchasing an additional 5,800 shares in the last quarter. Wells Fargo & Company MN increased its holdings in Puma Biotechnology by 36.5% during the 4th quarter. Wells Fargo & Company MN now owns 22,929 shares of the biopharmaceutical company's stock worth $70,000 after purchasing an additional 6,126 shares during the period. Tower Research Capital LLC TRC raised its position in Puma Biotechnology by 167.7% during the 4th quarter. Tower Research Capital LLC TRC now owns 10,137 shares of the biopharmaceutical company's stock valued at $31,000 after purchasing an additional 6,351 shares in the last quarter. Finally, Gateway Wealth Partners LLC purchased a new stake in shares of Puma Biotechnology in the 4th quarter worth $31,000. Hedge funds and other institutional investors own 61.29% of the company's stock.

Puma Biotechnology Stock Down 0.3 %

Puma Biotechnology stock traded down $0.01 during mid-day trading on Friday, reaching $3.00. 164,147 shares of the company were exchanged, compared to its average volume of 441,898. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.40 and a current ratio of 1.42. The firm has a market cap of $148.83 million, a P/E ratio of 6.25 and a beta of 1.34. The business has a fifty day moving average of $3.11 and a 200 day moving average of $3.03. Puma Biotechnology, Inc. has a 12-month low of $2.23 and a 12-month high of $5.26.

Puma Biotechnology (NASDAQ:PBYI - Get Free Report) last issued its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported $0.39 earnings per share for the quarter, topping analysts' consensus estimates of $0.10 by $0.29. Puma Biotechnology had a return on equity of 41.60% and a net margin of 9.56%. The firm had revenue of $59.10 million during the quarter, compared to analysts' expectations of $52.50 million. Research analysts anticipate that Puma Biotechnology, Inc. will post 0.31 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the company. StockNews.com upgraded Puma Biotechnology from a "buy" rating to a "strong-buy" rating in a research note on Friday. HC Wainwright reissued a "buy" rating and set a $7.00 target price on shares of Puma Biotechnology in a research report on Friday, February 28th.

Puma Biotechnology Profile

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.